Aclaris Therapeutics (NASDAQ:ACRS) – Investment analysts at Jefferies Group issued their Q1 2018 earnings per share estimates for shares of Aclaris Therapeutics in a research note issued on Tuesday, March 13th, according to Zacks Investment Research. Jefferies Group analyst D. Steinberg expects that the biotechnology company will earn ($0.94) per share for the quarter. Jefferies Group also issued estimates for Aclaris Therapeutics’ Q2 2018 earnings at ($1.09) EPS, Q3 2018 earnings at ($1.18) EPS, FY2018 earnings at ($4.38) EPS, FY2019 earnings at ($3.89) EPS, FY2020 earnings at ($2.25) EPS, FY2021 earnings at $0.46 EPS and FY2022 earnings at $2.51 EPS.
Other research analysts have also issued reports about the company. Cantor Fitzgerald reissued a “buy” rating and set a $50.00 target price on shares of Aclaris Therapeutics in a report on Monday, March 12th. BidaskClub raised Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, December 12th. Leerink Swann decreased their target price on Aclaris Therapeutics from $56.00 to $54.00 and set an “outperform” rating on the stock in a report on Tuesday, March 13th. Finally, Zacks Investment Research lowered Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. Aclaris Therapeutics presently has a consensus rating of “Hold” and an average price target of $43.50.
Shares of ACRS stock traded down $0.20 during trading on Thursday, reaching $16.46. 194,484 shares of the company’s stock were exchanged, compared to its average volume of 311,977. The firm has a market capitalization of $514.82, a PE ratio of -6.58 and a beta of 1.63. Aclaris Therapeutics has a twelve month low of $16.01 and a twelve month high of $33.10.
Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings results on Monday, March 12th. The biotechnology company reported ($0.80) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.90) by $0.10. The company had revenue of $1.00 million for the quarter, compared to analyst estimates of $0.80 million.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Cubist Systematic Strategies LLC bought a new stake in Aclaris Therapeutics in the 3rd quarter valued at $142,000. Teacher Retirement System of Texas bought a new stake in Aclaris Therapeutics in the 4th quarter valued at $200,000. Voya Investment Management LLC bought a new stake in Aclaris Therapeutics in the 2nd quarter valued at $247,000. Trexquant Investment LP bought a new stake in Aclaris Therapeutics in the 3rd quarter valued at $247,000. Finally, MetLife Investment Advisors LLC bought a new stake in Aclaris Therapeutics in the 4th quarter valued at $244,000. Institutional investors and hedge funds own 92.19% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Analysts Set Expectations for Aclaris Therapeutics’ Q1 2018 Earnings (ACRS)” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.dispatchtribunal.com/2018/04/07/jefferies-group-weighs-in-on-aclaris-therapeutics-incs-q1-2018-earnings-acrs.html.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.
Get a free copy of the Zacks research report on Aclaris Therapeutics (ACRS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.